Google backs a $60M transition round for FLX’s switch to a CCR4 strategy
FLX Bio isn’t the biotech it started out to be.
Formed as a spinout of Flexus after Bristol-Myers Squibb stepped in to buy the fledgling and an early-stage IDO1 therapy for the jaw-dropping sum of $1.25 billion, the biotech went on to pursue a FLT3/CDK4/6 drug for cancer. Then the founders — Terry Rosen and Juan Jaen — left to start their own companies and the new crew at FLX wound up terminating their original lead drug earlier this year and switching focus to another target in oncology: CCR4, focused on regulatory T cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
